DC ChemicalsChemicals for Life Science
sales@dcchemicals.com

DC59217 · Updated 24 October 2026

Arcturus lipid 2(ATX-0114)
Formulation & Performance

This edition organizes the previously reviewed, source-linked product record. It is not a new independent review of every paper or supporting file. Reported and calculated values retain their original labels.

Literature-reported formulation composition

Componentmol%Role
ATX-0114Not reportedIonizable lipid
PhospholipidNot reportedHelper phospholipid
Cholesterol (optional)Not reportedSterol
PEG-lipid conjugateNot reportedPEG lipid
Reported totalNot reportedSource values retained
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Not reported in the cited article
Patent general embodiment: 13:1 lipid:mRNA (w/w); not uniquely assigned to ATX-0114.
Patent discloses acidic encapsulation environments and subsequent aqueous formulations in general terms; ATX-0114-specific buffer/pH is not reported in the compound table.
Nucleic-acid cargo; the bioactivity table is labeled Factor VII knockdown.
In vivo study context; route is not specified in the ATX-0114 row of Table 1.
0.03 mg/kg in the patent bioactivity table.
Patent Table 1 bioactivity context; species and group size are not specified in the row.
Patent describes lipid particles formed by combining cationic/ionizable lipid, phospholipid, optional cholesterol and PEG-lipid with nucleic acid; a single ATX-0114-specific flow-rate recipe is not printed in the compound table.

Literature-reported performance for the cited formulation

Literature-reported90%0.03 mg/kg, patent compound-table bioactivity · ATX compound seriesUS20180170866A1 Table 1

Patent-reported ATX-0114 compound-table values

ParameterReported valueSource
Calculated c-LogD11.06US20180170866A1 Table 1
Calculated c-pKa9.59US20180170866A1 Table 1
Measured formulation pKa6.69US20180170866A1 Table 1
Bioactivity90% Factor VII knockdown at 0.03 mg/kgUS20180170866A1 Table 1

Additional reported findings

Patent particle-size context

The patent describes typical lipid-particle mean diameters of approximately 30-150 nm and broad encapsulation ranges, but these are invention-level ranges rather than ATX-0114-specific measurements.

· US20180170866A1 paragraphs [0130]-[0136].
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetPayne JE, Chivukula P. Ionizable Cationic Lipid for RNA Delivery. US20180170866A1, published 21 June 2018.
Patent values are reference data for the disclosed compound series and do not guarantee reproduction of Factor VII knockdown.

Public patent full text · Granted patent family